Search

Your search keyword '"Magyari, B."' showing total 19 results
Start Over Author "Magyari, B."
19 results on '"Magyari, B."'

3. Cardiopoietic cell therapy for advanced ischemic heart failure : results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Author

Bartunek, Jozef, Terzic, Andre, Davison, Beth A, Filippatos, Gerasimos S, Radovanovic, Slavica, Beleslin, Branko, Merkely, Bela, Musialek, Piotr, Wojakowski, Wojciech, Andreka, Peter, Horvath, Ivan G, Katz, Amos, Dolatabadi, Dariouch, El Nakadi, Badih, Arandjelovic, Aleksandra, Edes, Istvan, Seferovic, Petar M, Obradovic, Slobodan, Vanderheyden, Marc, Jagic, Nikola, Petrov, Ivo, Atar, Shaul, Halabi, Majdi, Gelev, Valeri L, Shochat, Michael K, Kasprzak, Jaroslaw D, Sanz Ruiz, Ricardo, Heyndrickx, Guy R, Nyolczas, Noémi, Legrand, Victor, Guédès, Antoine, Heyse, Alex, Moccetti, Tiziano, Fernandez Aviles, Francisco, Jimenez Quevedo, Pilar, Bayes Genis, Antoni, Hernandez Garcia, Jose Maria, Ribichini, Flavio, Gruchala, Marcin, Waldman, Scott A, Teerlink, John R, Gersh, Bernard J, Povsic, Thomas J, Henry, Timothy D, Metra, Marco, Hajjar, Roger J, Tendera, Michal, Behfar, Atta, Alexandre, Bertrand, Seron, Aymeric, Stough, Wendy Gattis, Sherman, Warren, Cotter, Gad, Wijns, W. i. l. l. i. a. m. Collaborators Clinical investigators, Dens, sites Belgium: Ziekenhuis Oost Limburg: J., Dupont, M., Mullens, W., Janssens, M., Dolatabadi, Hoˆpital Civil de Charleroi: D., De Bruyne, Y., Lalmand, J., Dubois, P., El Nakadi, B., Aminian, A., De Vuyst, E., Gurnet, P., Gujic, M., Blankoff, I., Guedes, CHU Mont Godinne UCL: A., Gabriel, L., Seldrum, S., Doyen, C., Andre´, M., Heyse, AZ Glorieux: A., Van Durme, F., Verschuere, J., Legrand, Domaine Universitaire du Sart Tilman: V., Gach, O., D’Orio, V., Davin, L., Lancellotti, P., Baudoux, E., Ancion, A., Dulgheru, R., Vanderheyden, OLV Ziekenhuis Aalst – Cardiologie: M., Bartunek, J., Wijns, W., Verstreken, S., Penicka, . M., Gelev, P. Meeus Bulgaria: Tokuda Hospital Sofia: V., Zheleva Kichukova, I., Parapunova, R., Melamed, R., Sardovski, S., Radev, O., Yordanov, A., Radinov, A., Nenov, D., Amine, I., Petrov, City Hospital Clinic Cardiology Center: I., Kichukov, K., Nikitasov, L., Stankov, Z., Stoyanov, H., Tasheva Dimitrova, I., Angelova, M., Dimitrov, E., Minchev, M., Garvanski, I., Botev, C., Polomski, P., Alexandrovska University Hospital, Vassilev, Sofia: D., Karamfiloff, K., Tarnovska Kadreva, R., Vladimirova, L., Dimitrov, G., Hadzhiev, E., Tzvetkova, G., Andreka, . M. Atanasova Hungary: Gottsegen Gyo¨ rgy Orszagos Kardiologiai Inte´zet: P., Fontos, G., Fabian, J., Csepregi, A., Uzonyi, G., Gelei, A., Edes, Debreceni Egyetem Orvos e´s Ege´szse´gtudomanyi Centrum Altalanos Orvostudomanyi Kar Kardiologia Inte´zet: I., Balogh, L., Vajda, G., Darago, A., Gergely, S., Fulop, T., Jenei, C., Horvath, Pe´csi Tudomanyegyetem Klinikai Ko¨zpont Szıvgyogyaszati Klinika: I., Magyari, B., Nagy, A., Cziraki, A., Faludi, R., Kittka, B., Alizadeh, H., Merkely, Semmelweis Egyetem Varosmajori Szıv e´s Ergyogyaszati Klinika: B., Geller, L., Farkas, P., Szombath, G., Foldes, G., Skopal, J., Kovacs, A., Kosztin, A., Gara, E., Sydo, N., Nyolczas, MH Ege´szse´gu¨gyi Ko¨zpont Kardiologiai Osztaly: N., Kerecsen, G., Korda, A., Kiss, . M., Borsanyi, T., Polgar, B., Muk, B., Sharif, Z. Bari Ireland: HRB Clinical Research Facility: F., Atar, Y. M. Smyth Israel:Western Galilee Hospital: S., Shturman, A., Akria, L., Kilimnik, M., Brezins, M., Halabi, Ziv Medical Center: M., Dally, N., Goldberg, A., Aehab, K., Rosenfeld, I., Levinas, T., Saleem, D., Katz, Barzilai Medical Center: A., Plaev, T., Drogenikov, T., Nemetz, A., Barshay, Y., Jafari, J., Orlov, I., Nazareth Hospital EMMS: M. Omory, N. Kogan Nielsen, Shochat, Hillel Yaffe Medical Center: M., Shotan, A., Frimerman, A., Meisel, S., Asif, A., Sofer, O., Blondheim, D. S., Vazan, A., Metra, L. Arobov Italy: A. O. Spedali Civili di Brescia: M., Bonadei, I., Inama, L., Chiari, E., Lombardi, C., Magatelli, M., Russo, D., Lazzarini, V., Carubelli, V., Vassanelli, AOUI Verona – Borgo Trento Hospital: C., Ribichini, Flavio Luciano, Bergamini, C., Krampera, Mauro, Cicoria, M. A., Zanolla, L., Dalla Mura, D., Gambaro, A., Rossi, A., Pesarini Poland: Jagiellonian University Department of Cardiac, G., Musialek, Vascular Diseases at John Paul II Hospital in Krakow: P., Mazurek, A., Drabik, L., Ka˛dzielski, A., Walter, Z., Dzieciuch Rojek, M., Rubis, P., Plazak, . W., Tekieli, L., Podolec, J., Orczyk, W., Sutor, U., Zmudka, K., Olszowska, M., Podolec, P., Gruchala, Uniwersyteckie Centrum Kliniczne: M., Ciecwierz, D., Mielczarek, M., Burakowski, S., Chmielecki, M., Zielinska, M., Frankiewicz, A., Wdowczyk, J., Stopczynska, I., Bellwon, J., Mosakowska, K., Nadolna, R., Wroblewska, J., Rozmyslowska, M., Rynkiewicz, M., Marciniak, I., Raczak, G., Tarnawska, M., Taszner, M., Kasprzak, Bieganski Hospital: J., Plewka, M., Fiutowska, D., Rechcinski, T., Lipiec, P., Sobczak, M., Weijner Mik, P., Wraga, M., Krecki, R., Markiewicz, M., Haval Qawoq, D., Wojakowski, Gornosla˛skie Centrum Medyczne Sla˛skie j. Akademii Medycznej: W., Ciosek, J., Dworowy, S., Gaszewska Zurek, E., Ochala, A., Cybulski, W., Jadczyk, T., Wanha, W., Parma, Z., Kozlowski, M., Dzierzak, M., Markiewicz Serbia: Clinical Hospital Center Zvezdara, M., Arandjelovic, Cardiology Clinic: A., Sekularac, N., Boljevic, D., Bogdanovic, A., Zivkovic, S., Cvetinovic, N., Loncar, G., Clinical Centre of Serbia, Beleslin, Cardiology Clinic: B., Nedeljkovic, M., Trifunovic, D., Giga, V., Banovic, M., Nedeljkovic, I., Stepanovic, J., Vukcevic, V., Djordjevic Dikic, A., Dobric, M., Obrenovic Kircanski, B., Seferovic, Cardiology Clinic: P., Orlic, D., Tesic, M., Petrovic, O., Milinkovic, I., Simeunovic, D., Jagic, Clinical Center of Kragujevac: N., Tasic, M., Nikolic, D., Miloradovic, V., Djurdjevic, P., Sreckovic, M., Zornic, N., Clinical Hospital Center Bezanijska Kosa, Radovanovic, Cardiology Department: S., Saric, J., Hinic, S., Djokovic, A., Ðordevic, S., Bisenic, V., Markovic, O., Stamenkovic, S., Malenkovic, V., Tresnjak, J., Misic, G., Cotra, D., Tomovic, L., Vuckovic, V., Clinic of Emergency Internal Medicine, Obradovic, Military Medical Academy: S., Jovic, Z., Vukotic, S., Markovic, D., Djenic, N., Ristic Andjelkov, A., Bayes Genis, D. Ljubinka Spain: Hospital Universitario Germans Trias I. Pujol: A., Rodriguez Leor, O., Labata, C., Vallejo, N., Ferrer, E., Batlle, M., Fernandez Aviles, Hospital General Universitario Gregorio Mara~non: F., Sanz Ruiz, R., Casado, A., Loughlin, G., Zatarain, E., Anguita, J., Ferna ndez Santos, M. E., Pascual, C., Bermejo, J., Hernandez Garcia, Hospital Clinico Universitario Virgen de la Victoria: J. M., Jimenez Navarro, M., Dominguez, A., Carrasco, F., Mu~noz, A., Garcia Pinilla, J. M., Ruiz, J., Queipo de Llano, M. P., Hernandez, A., Fernandez, A., Jimenez Quevedo, Hospital Clinico San Carlos: P., Guerra, R., Biagioni, C., Gonzalez, R. A., Gomez deDiego, J. J., Mansson Broberg, L. Perez de Isla Sweden: Karolinska University Hospital: A., Sylve´n, C., Leblanc, K., Winter, R., Blomberg, P., Gunyeli, E., Ruck, A., Silva, C., Fo¨rstedt Switzerland: CardioCentro Ticino, J., Moccetti, Switzerland: T., Rossi, M., Pasotti, E., Petrova, I., Crljenica, C., Monti, C., Murzilli, R., Su¨rder, D., Moccetti, M., Turchetto, L., Locicero, V., Chiumiento, L., Maspoli, S., Mombelli, M., Anesini, A., Biggiogero, M., Ponti, G., Camporini, C., Polledri, S., Hill, G. Dolci United Kingdom: Kings College Hospital: J., Plymen, C., Amin Youssef, G., Mcdonagh, T., Drasar, E., Mijovic, A., Jouhra, F., Mcloman, D., Dworakowski, R., Webb, I., Byrne, J., and Potter, V.

Subjects
0301 basic medicine, Male, Cardiopoiesis, Cardiovascular disease, Disease severity, Marker, Precision medicine, Regenerative medicine, Stem cell, Target population, Adult, Aged, Double-Blind Method, Female, Heart Failure, Humans, Mesenchymal Stem Cell Transplantation, Middle Aged, Myocardial Ischemia, Prospective Studies, Treatment Outcome, Young Adult, Cardiology and Cardiovascular Medicine, Cell- and Tissue-Based Therapy, mesenchymal stem-cells, 030204 cardiovascular system & hematology, Cardiorespiratory Medicine and Haematology, outcomes, Fast-Track Clinical Research, Sudden cardiac death, 0302 clinical medicine, Ischemia, cardiovascular disease, Clinical endpoint, target population, CHART Program, Ejection fraction, bone-marrow, Heart Failure/Cardiomyopathy, 3. Good health, Cohort, Cardiology, Fast Track, disease severity, delivery, medicine.medical_specialty, precision medicine, Clinical Sciences, regenerative medicine, 03 medical and health sciences, cardiopoiesis, Internal medicine, medicine, Adverse effect, marker, disease, business.industry, medicine.disease, mortality, Confidence interval, Clinical trial, stem cell, Editor's Choice, 030104 developmental biology, predictors, Cardiovascular System & Hematology, Heart failure, business
Abstract

Altres ajuts: This work was supported by Celyad, SA (Mont-Saint-Guibert, Belgium). Celyad has received research grants from the Walloon Region (Belgium, DG06 funding). Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort. This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein–Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann–Whitney estimator 0.54, 95% confidence interval [CI] 0.47–0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200–370 mL (60% of patients) (Mann–Whitney estimator 0.61, 95% CI 0.52–0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death. The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

Published
2017

4. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Author

Bonaca, MP, Bhatt, DL, Cohen, M, Steg, PG, Storey, RF, Jensen, EC, Magnani, G, Bansilal, S, Fish, MP, Im, K, Bengtsson, O, Ophuis, TO, Budaj, A, Theroux, P, Ruda, M, Hamm, C, Goto, S, Spinar, J, Nicolau, JC, Kiss, RG, Murphy, SA, Wiviott, SD, Held, P, Braunwald, E, Sabatine, MS, Morin, S, Dantzer, E, Acquilano, D, McGuire, RL, Gannon, JB, Gershman, E, Ahlbom, AM, Boberg, B, Abola, MT, Ardissino, D, Aylward, P, Corbalan, R, Dalby, A, Diaz, R, Hu, DY, Isaza, D, Kamensky, G, Kiss, R, Kontny, F, Lopez-Sendon, J, Medina, F, Montalescot, G, Nicolau, J, Paolasso, E, Parkhomenko, A, Van De Werf, F, Anderson, JL, White, HD, Verheugt, FWA, Pedersen, TR, DeMets, DL, Lowe, C, Arevalo, C, Awtry, E, Berger, C, Croce, K, Desai, A, Gelfand, E, Ho, C, Leeman, D, Link, M, Norden, A, Pande, A, Rost, N, Ruberg, F, Silverman, S, Singhal, A, Vita, J, Alvarisqueta, A, De Gennaro, N, Berli, M, Roude, AE, Di Gennaro, JA, Albisu, JF, Caccavo, A, Torres, M, Cuadrado, J, Bordoni, P, Cuello, J, Aviles, A, Glenny, A, Recoaro, R, Fernandez, R, Strada, BN, Fuentealba, V, Gallo, C, Duran, RG, Garcia, C, Hominal, M, Castoldi, M, Jure, H, Pacora, FF, Lorenzatti, A, Martinez, JM, Macin, S, Cocco, N, MacKinnon, I, Bagnato, MB, Marino, J, Cusimano, S, Arias, V, Focaccia, M, Muntaner, J, Mansilla, V, Poy, C, Prado, A, Paterlini, G, Montana, O, Camino, A, Sala, J, Luciani, C, Vico, M, Morell, Y, Dumont, C, Vottero, E, Zangroniz, P, Lescano, A, Morara, P, Marquez, LL, Patron, FR, Labarta, GB, Sivila, CD, Quiroga, AR, Maffei, L, Sassone, S, Rolandi, F, Vesentini, N, Carnero, G, Del Verme, S, Hershson, A, Figal, JC, Viso, ME, Hii, C, Smith, K, Singh, B, Acampo, M, Rogers, J, ODonoghue, M, Amerena, J, Long, A, Dart, A, Kay, S, Worthley, M, Nimmo, J, Lehman, R, Morrison, H, Dick, R, Savage, C, van Gaal, W, Park, M, Blombery, P, McCarthy, C, Oqueli, E, Hill, D, Sader, M, Vrachas, D, Purnell, P, Vibert, J, Collins, N, Gordon, A, Arstall, M, Rose, J, Aroney, C, Cleave, P, Fitzpatrick, M, Mackenzie, M, Garrahy, P, Hall, C, Nelson, G, Reid, E, Lee, A, Gibbs, J, Thompson, P, Crittenden, J, Hammett, C, Hindom, L, Antonis, P, Manzoney, A, Cross, D, Pollard, C, Brieger, D, Wu, J, Whelan, A, Tulloch, G, Taylor, A, Smith, B, Horowitz, J, Black, M, Boland, J, Malmendier, D, Celen, H, Wendelen, E, Claeys, M, Pieter, M, Cools, F, Simons, N, De Maeseneire, S, De Wolf, L, Brike, C, Dubois, P, Bolado, ACY, Foading-Deffo, B, Tahon, S, Friart, A, Arend, C, Gevaert, S, Verdegem, P, Marechal, P, Gits, F, Pierard, L, Celentano, C, Pirenne, B, Bouvy, C, Renkin, J, Huyberechts, D, Sinnaeve, P, De Velder, L, Stammen, F, Casier, T, Striekwold, H, Van den Broeck, D, Thoeng, J, Goris, R, Timmermans, P, Collard, SJ, Van De Borne, P, De Clippel, M, Wollaert, B, Jacobs, C, Vankelecom, B, Daelemans, Y, Vervoort, G, Drieghe, S, Vranckx, P, Janssen, A, Vrolix, M, Simenon, I, Wijns, W, Delacroix, H, Denie, D, Schoors, D, Lemoine, I, Cornelis, K, Willems, AM, Schroder, E, Domange, J, Greque, G, Machado, H, Armaganijan, D, Del Monaco, MI, da Silva, D, Nakazone, R, Dutra, O, Vaz, R, Daher, R, Rodrigues, D, Guimaraes, A, Teixeira, A, Saraiva, J, Leaes, P, Blacher, M, Maia, L, Nakazone, MA, Manenti, E, Ruschel, K, Marin-Neto, J, Pavao, R, Preto, R, Junior, AA, Oliveira, G, Rassi, S, Sampaio, D, Rossi, PR, dos Santos, L, de Souza, J, Lino, E, Filho, PP, Zucchetti, C, Gomes, M, de Paiva, A, Sousa, AC, Almeida, A, Botelho, R, da Silva, R, Giraldez, R, Franken, M, Faludi, A, Bertolami, M, Hernandes, M, Lucas, N, Carvalho, A, Bertolami, A, Precoma, D, Geralde, L, Pereira, A, Cesar, L, Mioto, B, Marino, R, Rabelo, W, dos Santos, F, Vidotti, M, Mangione, J, Mauro, M, Kormann, A, Ultramari, F, Zimmermann, S, Michalaros, Y, Fonseca, M, Sampaio, C, Eliaschewitz, F, Barbosa, E, Drews, C, de Lorenzo, A, Barros, C, Cancado, G, Neuesnchwander, F, Zimmermann, E, Chompalova, B, Denchev, S, Gocheva, N, Mihov, A, Mincheva, V, Gelev, V, Tisheva, S, Todorov, G, Goudev, A, Parvanova, Z, Todorova, M, Mitkova, M, Smilov, L, Yakovova, S, Milanova, K, Aleksov, N, Mollov, M, Shishmanova, D, Hristova, K, Uzunangelov, Y, Peltegov, V, Karamitev, G, Benov, H, Vasileva, D, Parishev, G, Milcheva, N, Avramov, D, Miteva, B, Stoyanovski, V, Pencheva, G, Nikolova, L, Stancheva, N, Nyagina, M, Markov, D, Spirova, D, Peneva, Y, Peshkov, O, Mitkova, L, Mandzhukova, S, Rangelova, V, Ivanov, K, Krusheva, B, Raycheva, V, Gergova, V, Goranov, K, Stoykov, A, Staleva, M, Rashkova, V, Postadzhian, A, Krancheva, V, Lulova, E, Delchev, G, Cantor, W, Constance, C, Gosselin, G, Marr, D, Pandey, A, Pesant, Y, Pouliot, J, Gladstone, P, McPherson, T, Rupka, D, Saw, J, St-Amour, E, Syan, G, Syan, R, Rosenbloom, A, Vizel, S, Della Siega, A, Halperin, F, Nigro, F, Chehayeb, R, Fell, D, Labonte, R, Nawaz, S, Gupta, M, Ma, P, Glanz, A, Kouz, S, Bhargava, R, Dion, D, Dupuis, R, Grondin, F, Wong, B, Sabbah, E, Hui, W, Belisle, P, Tymchak, W, Montigny, M, Lonn, E, Bose, S, Kincade, D, Gallo, R, Lamy, A, Bell, A, Lemay, M, Bata, I, Kostuk, W, Cheung, S, Petrella, R, Lubelsky, B, Berlingieri, J, Fortin, C, DeYoung, J, Babapulle, M, Landry, D, Gupta, A, Bertrand, O, Jadin, M, Robbins, K, Gauthier, MF, Masson, C, Reyes, V, O'Blenis, G, Clarus, S, Sardin, V, Marquette, S, Bozek, B, Spurrell, D, Thiessen, S, Fox, R, Tremblay, I, Singh, J, Samms, S, Ross, B, Solomon, P, Nelson, S, Roberts, P, Forsyth, C, Lepage, C, McPherson, C, Dewar, C, Dela Cruz, C, Louch, D, Vilag, C, Roy, M, Stata, C, Morissette, A, Ouimet, F, Bilodeau, N, Chausse, I, Kvill, L, Chartrand, MJ, Harris, L, Bolduc, H, Magi, A, Jule, P, Valley, S, Morrissette, J, Power, P, Kailey, P, Thomas, A, Wright, D, Carr, S, Cleveland, T, Dihel, C, Coldwell, J, Schellenberg, S, Viau, C, Watt, M, Corke, R, Shea-Landry, G, Gandhi, A, Tishler, S, Prieto, JC, Noriega, V, Cobos, L, Obreque, C, Potthof, S, Zapata, J, Lucero, F, Luque, M, Pincetti, C, Torres, G, Yanez, M, Vasquez, C, Manriquez, L, Espinoza, MJ, Yovaniniz, P, Grandon, M, Castro, P, Llevaneras, S, Lanas, F, Hidalgo, J, Arriagada, G, Villan, C, Florenzano, F, Chacon, MV, Rodriguez, M, Barreda, B, Raffo, C, Reyes, T, Hu, D, Liu, W, Tan, N, Feng, Y, Dong, Y, Yang, D, Liao, Y, Wei, F, Wei, M, Yan, M, Yan, X, Wang, S, Li, Y, Yuan, Z, Xiong, Y, Zhu, J, Li, S, Ma, G, Chen, L, Li, Z, Liu, Y, Xiong, W, Pang, W, Chen, Y, Lu, G, Chen, Z, Zhao, S, Zhou, H, Huang, J, Gang, Y, Chai, Y, Yang, X, Zhang, Z, Mu, Z, Hernandez, E, Mora, C, Maria, E, Catalan, Y, Reynales, H, Huertas, D, Molina, D, Rendon, N, Sanchez, G, Tellez, R, Botero, R, Salazar, P, Vesga, B, Delgado, P, Herrera, M, Perez, D, Jaramillo, N, Toloza, R, Orozco, A, Bustamante, Y, Jaramillo, C, Garces, G, Saaibi, J, Castillo, J, Arana, C, Gonzalez, M, Urina, M, Ramirez, N, Manzur, F, Rosales, D, Quintero, A, Gonzalez, E, Accini, J, Reyes, M, Elbl, L, Malecha, J, Stanek, L, Jerabek, O, Lubanda, H, Kos, P, Zidkova, E, Vlckova, D, Naplava, R, Ludka, O, Ludkova, A, Soucek, M, Kuchar, J, Poloczek, M, Wasserburger, B, Panovsky, R, Linhart, A, Rihacek, I, Macha, J, Grunfeldova, H, Spinarova, L, Zanova, M, Bren, J, Zarembova, J, Cermak, O, Sembera, Z, Svobodova, I, Monhart, Z, Pleva, L, Sipula, J, Polasek, R, Kolmas, P, Dedek, V, Janota, T, Stipal, R, Kucera, D, Bednarova, J, Broulova, P, Lukac, M, Hanak, P, Reichert, P, Bouchal, P, Turkova, N, Krocova, E, Petrova, I, Matyasek, I, Brychta, T, Machova, V, Marusincova, I, Sperlingova, B, Macquin-Mavier, T, Khalife, K, Galley, D, Elhadad, S, Decoulx, E, Cottin, Y, Coisne, D, Bonnet, JL, Ferrari, E, Range, G, Cayla, G, Goralski, M, Furber, A, Elbaz, M, Aboyans, V, Poulard, JE, Zemour, G, Labeque, JN, Hirsch, JL, Vaquette, B, Livarek, B, Igigabel, P, Lafitte, S, Oudghiri, M, Bertin, B, Beitar, T, Merkling, D, Beltra, C, Maubert, A, El Jarroudi, M, Bichat, F, Berger, N, Fiacchetti, C, Douillet, M, Laure, C, Leperchois-Jacquey, C, Miran, S, Cornet, C, Rosolin, N, Pradel, V, Leparree, S, Doux, N, Mais, C, Sevilla, J, Laurencon, V, Georges, J, Gilard, V, Duprat, C, Giannitsis, E, Schenkenberger, I, Appel, KF, Toursarkissian, N, Bott, J, Nischik, R, Schmidt, E, Jung, T, Steiner, S, Khariouzov, A, Heuer, H, Kadel, C, Hanefeld, M, Weil, J, Koenig, W, Horacek, T, Muenzel, T, Brachmann, J, Weber, D, Wittlich, N, Stellbrink, C, Dungen, HD, Leschke, M, Zeymer, U, Dorsel, T, Voehringer, HF, Dissmann, M, Vom Dahl, J, Derwahl, KM, Trenk, D, Frey, N, Schroeder, T, Foerster, A, Bartels, R, Kisselbach, C, Deigentasch, H, Dreykluft, K, Becker, P, Scheuren, A, Erdas, M, Wipper, J, Schmidt, A, Henzler, A, Winter, K, Fischer, S, Kopf, S, Laschewski, B, Rahn, G, Schrapel, C, Miodek, M, Hildenbrand, S, Fink, P, Gebel, G, Goebel, U, Siepmann, C, Drexler, A, Maiwald, A, Blaich, B, Baumann, S, Iselt, M, Gebhardt, S, Kazcmarek, N, Krug-Hoeren, B, Traubler, B, Nicula, D, Reichenbach, D, Langer, C, Kiroglu, K, Riedel, S, Schulte, M, Borst, M, Katona, A, Vertes, A, Merkely, B, Ungi, I, Kiraly, C, Zolyomi, S, Horvath, I, Lupkovics, G, Edes, I, Simon, E, Czuriga, I, Laszlo, Z, Kancz, S, Takacs, J, Papp, A, Czigany, A, Muller, G, Tas, AS, Polgar, P, Jilling, MJ, Bartal, G, Kerkovits, A, Bodi, M, Benczur, B, Valco, J, Erdei, F, Sebo, J, Korda, A, Turi, T, Becker, D, Kalapos, A, Bosko, M, Pap, G, Magyari, B, Basa, A, Jenei, C, Bakai, J, Unterberger, K, Vas, K, Fulop, G, Nagy, M, Takacs, A, Mate, Z, Szilagyi, A, Nagy, K, Svab, M, Kis, E, Horthy, R, Kantor, F, Sperr, E, Bajcsi, E, Bujdoso, A, Martina, P, Fiscella, A, Marenzi, G, Tamburino, C, Terrosu, P, Presbitero, P, Cuccia, C, Bovenzi, F, Berti, S, Colivicchi, F, Paloscia, L, Scherillo, M, Tartaglione, S, Della Rovere, F, De Cesare, N, Manari, A, Astarita, C, Oltrona, L, Marzilli, M, Caldarola, P, Merlini, P, Celentano, A, Di Sciascio, G, Pajes, G, Silvestri, O, Delfino, R, Bassani, F, Cavallini, C, Fattore, L, Di Lorenzo, L, Notarangelo, F, Stefanin, C, Giacoppo, M, Rubino, M, Dammino, L, Chessa, P, Di Pizzo, A, Musmeci, G, Mazzoni, A, Tyack, K, Aiello, A, Mascellanti, M, Formigli, D, Guglielmino, G, Bernabo, P, Bocciarelli, M, De Iaco, G, Russo, G, Rizzotti, D, Orsini, E, Saponetti, LS, Babbolin, M, De Divitiis, M, Patti, G, Monti, F, Silvestri, N, Valbusa, A, Lazzarotti, M, Puccetti, L, Grikstaite, E, Patrizi, G, Bosco, B, Marchegiano, R, Takenaka, T, Ono, M, Suzuki, M, Hasegawa, K, Domae, H, Fukui, K, Iseki, H, Aoyama, T, Suzuki, C, Sakai, R, Hashimoto, T, Inoko, M, Sasaki, T, Kataoka, T, Okutsu, M, Yasaka, Y, Miyamoto, T, Tomobuchi, Y, Tamura, R, Hosokawa, S, Komura, Y, Takahashi, N, Mima, T, Sadamatsu, K, Fujimoto, K, Matsumura, T, Koide, S, Himi, T, Hashimoto, Y, Yamasaki, M, Okubo, M, Takase, H, Morii, I, Utsu, N, Higashino, Y, Shigematsu, S, Nakagawa, T, Ota, T, Takahashi, W, Kakishita, M, Hayashi, Y, Momiyama, Y, Baden, M, Saeki, T, Hiroi, S, Wada, A, Nakata, A, Nishi, Y, Hirasawa, S, Shibata, Y, Fukuzawa, S, Machida, M, Takama, N, Teranishi, J, Sakuma, K, Abe, Y, Suzuki, A, Yamazaki, A, Nakachi, T, Nagayama, H, Fujino, S, Tsurukai, A, Nojima, S, Ishiguchi, Y, Hada, K, Nakatani, K, Yamamoto, K, Matsuo, A, Yamaguchi, E, Ito, S, Matsuda, M, Onishi, M, Kawanishi, Y, Ohashi, Y, Ochi, K, Miyamoto, S, Ichishita, Y, Iwamoto, H, Sagara, Y, Komori, M, Matsumura, A, Nakashima, R, Kondo, M, Suzuki, K, Kodama, S, Kotajima, H, Fujimoto, N, Honda, K, Iwamoto, M, Okada, S, Ichinose, K, Takinami, N, Takagi, E, Nakano, A, Tomari, H, Yokoyama, T, Matsui, Y, Nishimura, N, Asano, T, Mochiduki, A, Yamashita, S, Okino, S, Hirabayashi, K, Funada, R, Wardeh, AJ, Dille, C, De Melker, EC, van der Spoel, A, Willems, FF, Maassen, E, Westendorp, ICD, Zweers, D, Dunselman, PHJM, Blom, L, Ronner, E, Wissenburg, A, van der Sluis, A, Badings, EA, den Hartog, FR, Singerling, M, Aksoy, I, Heil, A, Tjeerdsma, G, van Daalen, C, Lenderink, T, Lardenois, R, Prins, FJ, Rutten, R, Plomp, J, Veldmeijer, S, De Vries, RJM, Krikken, J, Ophuis, TAJMO, Buvelot, S, Bos, RJ, Tan-Urgert, B, Werner, HA, Wittekoek, M, van Daele, MERM, Bouwens, M, Oomen, A, Meijlis, P, Verheul, JA, Uiterwaal, H, Knufman, N, de Lange, H, Bartels, GL, Hendriks-Van Woerden, M, van Bemmel, B, Beyering, M, Zwart, PAG, Teng, Y, van der Zwaan, C, Havenaar, J, Hermans, WRM, de Graauw, J, Hamraoui, K, Dabrowska, K, de Nooijer, C, Groenenberg, I, Kietselae, BLJH, Muis, L, Hamer, BJB, Hobe, C, van Eck, JWM, Elzebroek, N, Tans, JGM, Stapel, AGT, Nierop, PR, Dirks, M, Kuijper, AFM, Schiks, M, de Groot, MR, Post, G, ten Berg, JM, Bras, R, Koolen, JJ, van Leur, L, Herrman, JPR, Roelse, A, Ebink, C, Jones, B, Lipsic, E, Couperus, M, Bogaard, K, Dijk, A, Pettersen, KI, Fortun, M, Gullestad, L, Stueflotten, W, Popovic, I, Sobye, ET, Hogalmen, G, German, M, Hysing, J, Flagstad, E, Slettom, G, Nordrehaug, JE, Isaksen, A, Graven, T, Haug, H, Sandvik, J, Thunhaug, H, Ronning, PB, Gravrok, B, Lappegard, KT, Enebakk, T, Ronnevik, P, Ronnevik, T, Hurtig, U, Skanke, E, Omland, T, Tobiassen, GM, Berrospi, P, Ragas, Y, Bustamante, G, Marruffo, Y, Chavez, E, Chaname, A, Heredia, J, Gamero, K, Lema, J, Carrion, AM, Rodriguez, V, Cabanillas, N, Rodriguez, A, Zena, N, Segura, L, Rojas, C, Toce, L, Carrera, J, Orihuela, B, Del Portal, M, Roldan, Y, Roldan, G, Rodriguez, J, Chavez, C, Luna, G, Parra, J, Ramos, J, Mogrovejo, W, Godoy, J, Talledo, MZ, Diestra, J, Godoy, A, Matta, M, Pino, C, Vergara, R, Chois, A, Guillen, AM, Medina, J, Chirinos, J, Paredes, A, Quiroz, M, Camacho, L, Gil, M, Cerbito, S, Beltran, J, Tanglao, M, Uy, N, Busa, J, Rogelio, G, Arbis, MG, Prado, JP, Miranda, M, Sulit, DJ, Dioquino, R, Sevilla, R, Soriano, RA, Rosita, RR, Amazona, A, Atilano, A, Lim, E, Ebo, G, Maglasang, P, Palmes, P, Loreno, CA, Tirador, L, Alagban, C, Roxas, DJ, Roxas, JF, Cheng, F, De Guzman, S, Morales, D, Mararac, T, Barbas, B, Barbas, K, Ferrolino, A, Baysac, C, Llarena, AC, Julianes, C, Torun, A, Dalkowski, M, Widejko, K, Derlaga, B, Laskowska, E, Dudek, D, Dziewierz, A, Jozwa, R, Busz-Papiez, B, Pawlowicz, L, Kaczmarczyk, M, Jaworska, K, Skonieczny, G, Kopaczewski, J, Wujkowski, M, Krasowski, W, Krzyzanek, P, Kubica, J, Kozinski, M, Miekus, P, Glaza, M, Podolec, P, Wilkolek, P, Piepiorka, M, Piepiorka-Broniecka, M, Pluta, W, Ploch, M, Rynkiewicz, A, Mosakowska, K, Szpajer, M, Lesinski, D, Szwed, H, Jasek, S, Sciborski, R, Piotrowicz, R, Musial, W, Lisowska, A, Rekosz, J, Kasznicka, M, Korzeniak, R, Staneta, P, Konczakowski, P, Waluszek-Konczakowska, I, Cymerman, K, Lubinski, A, Grycewicz, T, Hiczkiewicz, J, Plucinski, M, Korol, M, Szczech, J, Hawro, M, Skorski, M, Cichon, K, Jankowski, M, Cygler, J, Ottomanska-Cygler, M, Korecki, J, Gulaj, E, Zechowicz, T, Zechowicz, M, Goch, A, Topolinski, B, Ogorek, M, Szczepanska, A, Wojewoda, P, Jagoda, E, Krzyzanowski, W, Muzyk-Osikowicz, M, Jaszczurowski, W, Stasiewski, A, Wietrzynska, J, Miklaszewicz, B, Beme, A, Sudnik, W, Matys, U, Ponikowski, P, Powierza, S, Kim, YH, Choi, DJ, Seung, KB, Lim, DS, Lee, SH, Kim, HS, Bae, JH, Hong, TJ, Hong, MK, Tahk, SJ, Kim, YJ, Yoon, J, Jeong, MH, Chae, JK, Cho, MC, Hong, SK, Hur, SH, Jeong, JO, Her, SH, Lee, JM, Chang, KC, Yoon, CH, Chang, K, Park, J, Choi, S, Park, K, Bae, Y, Lee, H, Kim, BK, Yoon, MH, Park, JS, Jang, H, Kim, C, Cho, EJ, Bae, J, Lee, D, Lee, J, Choi, YY, Dimulescu, D, Vintila, M, Fruntelata, A, Pirvu, O, Stanciulescu, G, Giuca, A, Militaru, C, Radoi, M, Bobescu, E, Crisu, D, Creteanu, M, Minescu, B, Bolohan, F, Manitiu, I, Bengus, C, Iosipescu, L, Ciobotaru, V, Basarab, G, Benedek, I, Constantinescu, M, Cristea, M, Capalneanu, R, Tatu-Chitoiu, G, Huidu, S, Protopopescu, L, Greavu, M, Diaconu, M, Blajan, D, Istratoaie, O, Lican, G, Bisoc, A, Doka, B, Jemna, D, Parasteac, M, Serban, L, Mihai, M, Cioca, G, Ochean, V, Costache, L, Andor, M, Stoica, D, Benedek, T, Sava, N, Anciu, M, Mot, S, Cornaciu, S, Boldueva, S, Golitsyn, S, Karpov, Y, Kobalava, Z, Konstantinov, V, Kuimov, A, Ezhov, M, Panov, A, Novikova, T, Simanenkov, V, Smolenskaya, O, Tsyba, L, Vishnevsky, A, Yakhontova, P, Kislyak, O, Demchenko, E, Yakovlev, A, Ermoshkina, L, Arkhipov, M, Galyavich, A, Strongin, L, Kosmacheva, E, Goloshchekin, B, Sidorenko, B, Izmozherova, N, Shustov, S, Orlikova, O, Lukyanov, Y, Koziolova, N, Nedogoda, S, Statsenko, M, Kotelnikov, M, Osipenko, M, Oshchepkova, E, Bolieva, L, Ryamzina, I, Pavlysh, E, Samokhvalova, M, Mironova, N, Buza, V, Shavarov, A, Serebrenitskaya, M, Khomyakova, L, Safarova, M, Lohovinina, N, Staroverov, I, Bitakova, F, Zakharova, N, Khurs, E, Belenky, D, Kositsyn, D, Rovnykh, Y, Kasatova, T, Lubinskaya, E, Omelchenko, M, Slukhaenko, I, Kozulin, A, Baleeva, L, Pochinka, I, Kizhvatova, N, Laptev, I, Bugrimova, M, Popov, A, Kovalevskaya, E, Orlikov, E, Paltsman, Z, Lamden, D, Surovtseva, M, Tsoma, V, Derevjanchenko, M, Streltsov, S, Bikbulatova, E, Dmitriev, V, Byazrova, S, Khovaeva, Y, Komandenko, O, Dlesk, A, Urban, M, Vinanska, D, Dzupina, A, Hranai, M, Cisar, P, Toth, P, Paulov, S, Sivak, V, Bolvanska, N, Pella, D, Palka, J, Nedelova, I, Benacka, J, Gergel, V, Hatalova, K, Kohut, P, Kovar, F, Knazeje, M, Macek, V, Sinska, R, Bugan, V, Badenhorst, JCW, Erasmus, L, Burgess, LJ, de Necker, I, Corbett, CH, Fouche, L, Dawood, SY, Conradie, C, Delport, EF, Kruger, M, Ebrahim, I, Bobak, C, Nethononda, MR, Nunkoo, T, van Rensburg, FPJ, Middle, R, Horak, AR, Henley, L, Mabin, TA, King, A, Ranjith, N, Ramdas, S, Roodt, A, Coetsee, E, Theron, H, Karsten, M, Van Zyl, LJ, Roscher, M, Venter, TP, de Kock, L, Becker, AC, Swanepoel, J, Ismail, SM, Dalby, AJ, Allman, J, Roux, JP, Christie, H, Naidoo, DP, Vawda, GHM, Manga, P, Olckers, W, Mpe, MT, Farrell, BM, Areses, ELD, Lopez, SV, Fernandez, JMC, Roldan, JG, Pavia, PG, Segovia, AG, Puig, JG, Garcia, VC, Aguilera, RM, Munoa, MD, Cortada, JB, Cereto, PC, Perez, IP, Cid, LP, Basilio, EG, Guerra, PC, Ortiz, AF, Balcones, LDV, Vera, TR, Martinez, JMG, Galvan, ED, Caballero, AH, Blanco, VMR, Lopez, JMR, Franco, MRP, Soriano, FR, Porcar, LC, Fillat, ARC, Moreno, SG, Montejano, MG, Guerrero, JMD, Coronado, JLB, Eizagaechevarria, NM, Araucua, GN, Rubio, AM, Roca, MC, Marimon, XGM, Perales, MV, Gonzalez, AB, Sastre, MP, Juanatey, JRG, Acuna, JMG, Al-Khalili, F, Lof, P, Bandh, S, Myllyla, L, Christensen, K, Johansson, K, Dellborg, M, Hultsberg-Olsson, G, Alstrom, P, Damm, TL, Erlinge, D, Brolin, G, Ravn-Fischer, PA, Johansson, P, Andreen, S, Linderfalk, C, Ram, B, Lindholm, CJ, Assarsson, E, Mooe, T, Lindberg, A, Paren, P, Moodh, J, Svensson, P, Andersson, I, Wodlin, P, Raschperger, A, Skogvard, P, Koch, A, Lind, N, Osberg, L, Nilsson, C, Svensson, K, Bengtsson, M, Samad, B, Nilsson, M, Berglund, E, Lundgren, C, Lindmark, K, Sundholm, C, Aladellie, L, Welin-Berger, B, Guneri, S, Dogan, NB, Ersanli, M, Coskun, U, Cayli, M, Seker, T, Camsari, A, Ozcan, T, Ongen, Z, Karadag, B, Boyaci, B, Sezenoz, B, Pekdemir, H, Hidayet, S, Erol, M, Yalcin, A, Sezer, M, Emet, S, Bozkurt, E, Ozen, MB, Lutay, Y, Dyadyk, O, Kholopov, L, Rudyk, I, Shaposhnikova, Y, Chopey, I, Ternuschak, T, Reshotko, D, Popova, G, Batushkin, V, Gema, A, Vizir, V, Berezyn, O, Lutai, M, Tovstukha, V, Shumakov, V, Pogurelska, O, Sirenko, Y, Rekovets, O, Kraiz, I, Kamenska, E, Tseluyko, V, Yakovleva, L, Yena, L, Artemenko, V, Koval, O, Kaplan, P, Karpenko, O, Nevolina, I, Bazilevych, A, Harbar, M, Rudenko, L, Beregova, O, Mostovyi, Y, Rasputina, L, Vatutin, M, Shevelok, A, Kovalenko, V, Polenova, N, Amosova, K, Tkachenko, L, Volkov, V, Zaprovalna, O, Storey, R, Thomas, M, Pell, A, Moriarty, A, Kinnin, M, Ahsan, A, Burton, J, ORourke, B, Young, J, Lang, C, Forbes, J, Rowlands, D, Hamill, S, Sprigings, D, Cadd, A, de Belder, M, Atkinson, B, Ramsey, M, Fagan, JC, Pye, M, Wright, L, Keeling, P, Hughes, D, Fraser, D, Phillips, H, Muthusamy, R, Lawan, M, Levy, T, Kennard, S, Bodalia, B, Mottram, J, Calvert, J, Brodie, K, Gunstone, A, Douglas, C, Trouton, T, Hunter, B, Gerber, R, Pepper, H, Mathur, A, Andiapen, M, Baumbach, A, Bowles, R, Hildick-Smith, D, McGregor, A, Loh, I, Plocky, J, Adams, K, Clemmer, K, Aggarwal, K, Burkhardt, V, Costa, M, Lemmertz, K, Anderson, J, York, T, Angiolillo, D, Green, E, Sperling, M, Vasquez, E, Aycock, G, Tatum, D, Amin, J, Davidson, A, Hendrix, E, Shepard, L, Strain, J, Michel, K, Talano, J, Szalanski, N, Berk, M, Ibarra, M, Bhagwat, R, Winterrowd, D, Bilazarian, S, Marsters, M, Blonder, R, Graf, L, Brilakis, E, Roesle, M, Byrd, L, Sullivan, A, Longo, J, Pennella, A, Westerhausen, D, Weil, R, Carr, K, Piazza, J, Carr, KW, Castello, R, Hawks, M, Chandna, H, Holly, D, Chandrashekhar, YS, Molinaro, N, Carter, M, Antonino, M, Kosmicki, D, Kelley, M, Richwine, R, Pazier, P, Glasgow, B, Bresee, S, Alexander, J, Concha, M, Martinez, E, Connelly, T, Schenks, R, Cooper, M, Garman, V, Condit, J, White, A, Fialkow, J, Mckercher, M, Luna, M, Soto, G, Prodafikas, J, Rambaud, B, Donovan, J, Mudd, D, Doty, W, Parsons, T, D'Urso, M, Bies, J, Han, J, Treadwell, M, Erickson, B, Dahl, P, Fattal, P, Braem, J, Felten, W, Prior, J, French, W, Barillas, O, Berger, R, Genova, E, Gelernt, M, Cockrell, D, Miller, G, Dumka, K, Gill, S, Elliot, S, Goldberg, R, Barrett, M, Gordon, P, Stern, L, Ayres, T, Rhule, V, Gupta, D, Holton, T, Haddad, T, Jain, J, Hakas, J, McSorley, J, Hamroff, G, Hollenweger, L, Wainwright, W, Jones, S, Casagrande, M, Casagrande, MG, Effat, M, Mardis, R, Henderson, D, Millard, D, Hermany, P, Meissner-Dengler, S, Hinchman, D, Luck, K, Hodson, R, Severson, L, Horwitz, P, Miller, K, Isserman, S, Moore, C, Jan, M, Bilyk, O, Kersh, R, DaCosta, A, Kim, E, Gonzales, C, Kmetzo, J, Taylor, D, Knutson, T, Belanger, B, Hage-Korban, E, Harrington, A, Murdock, D, Heiman, M, Dandekar, U, Khan, M, Khan, G, Lui, H, Holman, L, MacDonald, L, Derbyshire, S, Watkins, K, Mayer, N, Mitchell, B, McCullum, K, Delio-Cox, B, Mckay, R, Cloutier, J, McKenzie, M, Rodkey, K, McLaurin, B, Lack, A, Minisi, A, Jeter, D, Mitchell, R, Keane-Richmond, P, Stine, R, Bullivant, M, Morford, R, White, J, Oberoi, M, Geraldo-Abache, A, O'Dea, D, Mehta, R, Tang, N, Ong, S, Edwards, M, Osborne, J, Alonzo, C, Lev, V, Monroe, J, Popeil, L, Sorrentino, N, Portelli, J, Landi, T, Potu, R, Smith, N, Prashad, R, McDonough, C, Qureshi, M, Howe, A, Raikhel, M, Arsate, M, Rogers, W, Saag, L, Sangrigoli, R, Schwarz, L, Abu-Fadel, M, Hagee, A, Kinnaman, S, McDaniel, V, Wilson, V, Purcell, T, Roberts, J, Riofrio, K, Shah, U, Narang, S, Gredler, F, Knap, P, Shanes, J, Hansen, C, Sharma, M, Gibson, T, Sheldon, W, Bohn, A, Siegel, C, Tibbits, L, Singh, V, Nelson, M, Singh, N, Logwood, D, Randhawa, P, Vargas, B, Stegemoller, R, Cole, B, Aggarwal, R, Johnson, M, Steinhoff, J, Dunaway, B, Patel, K, Boomer, L, Taheri, H, Morgan, K, Tahirkheli, N, Santos, A, Thadani, U, Alexander, D, Bennett, W, Kelley, E, Thomas, J, Macnicholas, D, Varma, S, Evans, S, Vlastaris, A, Bittel, B, Voyce, S, Mack, B, Weiss, R, Fournier, T, Whitney, R, Orosco, C, Willis, J, VonGerichten, S, Wiseman, A, Sharrow, A, Wohns, D, Schuitema, J, Amin, M, Ramus, A, Wilson, W, Moeller, C, Newell, M, Tindell, L, Rivera, W, Kwierant, J, Bretton, E, Corbin, B, Labroo, A, Lopez, C, Brown, C, Craig, M, Lucca, M, Keinanen, T, Eisenberg, S, Fielding, M, Doorey, A, Squire, A, Suresh, D, Frost, J, Teklinski, A, Stone, B, Waksman, R, Griffin, S, Wharton, W, Blakely, J, Fishbein, G, Weller, C, Camp, A, Fisher, S, Meholick, A, Hejna, E, Anderson, R, Long, S, Parikh, S, Norton, N, Vijay, N, Washam, M, Smith, S, and Stepanov, N

Abstract

BACKGROUND The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y(12) receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS We randomly assigned, in a double-blind 1: 1: 1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P = 0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P = 0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P < 0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.)

Published
2015

7. Poster Session 5: Saturday 10 December 2011, 08:30-12:30 * Location: Poster Area

Author

Gong, L., primary, Ye, Z., additional, Zeng, Z., additional, Xia, M., additional, Zhong, Y., additional, Yao, Y., additional, Lee, E., additional, Ionescu, A., additional, Dwivedi, G., additional, Mahadevan, G., additional, Jiminez, D., additional, Frenneaux, M., additional, Steeds, R., additional, Moore, C., additional, Samad, Z., additional, Jackson, K., additional, Castellucci, J., additional, Kisslo, J., additional, Von Ramm, O., additional, D'ascenzi, F., additional, Zaca', V., additional, Cameli, M., additional, Lisi, M., additional, Natali, B., additional, Malandrino, A., additional, Mondillo, S., additional, Barbier, P., additional, Guerrini, U., additional, Franzosi, M., additional, Castiglioni, L., additional, Nobili, E., additional, Colazzo, F., additional, Li Causi, T., additional, Sironi, L., additional, Tremoli, E., additional, Clausen, H., additional, Macdonald, S., additional, Basaggianis, C., additional, Newton, J., additional, Bennati, E., additional, Reccia, R., additional, Bigio, E., additional, Maccherini, M., additional, Chiavarelli, M., additional, Henein, M., additional, Floria, M., additional, Jamart, J., additional, Arsenescu Georgescu, C., additional, Mantovani, F., additional, Barbieri, A., additional, Bursi, F., additional, Valenti, C., additional, Quaglia, M., additional, Modena, M., additional, Kutty, S., additional, Gribben, P., additional, Padiyath, A., additional, Polak, A., additional, Scott, C., additional, Waiss, M., additional, Danford, D., additional, Bech-Hanssen, O., additional, Selimovic, N., additional, Rundqvist, B., additional, Schmiedel, L., additional, Hohmann, C., additional, Katzke, S., additional, Haacke, K., additional, Rauwolf, T., additional, Strasser, R., additional, Tumasyan, L. R., additional, Adamyan, K., additional, Kosmala, W., additional, Derzhko, R., additional, Przewlocka-Kosmala, M., additional, Mysiak, A., additional, Stachowska, B., additional, Jedrzejuk, D., additional, Bednarek-Tupikowska, G., additional, Chrzanowski, L., additional, Kasprzak, J., additional, Wojciechowska, C., additional, Wita, K., additional, Busz-Papiez, B., additional, Gasior, Z., additional, Mizia-Stec, K., additional, Kukulski, T., additional, Gosciniak, P., additional, Sinkiewicz, W., additional, Moelmen, H., additional, Stoylen, A., additional, Thorstensen, A., additional, Torp, H., additional, Dalen, H., additional, Groves, A., additional, Nicholson, G., additional, Lopez, L., additional, Goh, C.-W., additional, Ahn, H., additional, Byun, Y., additional, Kim, J., additional, Park, J., additional, Lee, J., additional, Kim, B., additional, Rhee, K., additional, Kim, K., additional, Yoon, H., additional, Hong, Y., additional, Park, H., additional, Ahn, Y., additional, Jeong, M., additional, Cho, J., additional, Kang, J., additional, Grapsa, J., additional, Dawson, D., additional, Karfopoulos, K., additional, Jakaj, G., additional, Punjabi, P., additional, Nihoyannopoulos, P., additional, Ruisanchez Villar, C., additional, Lerena Saenz, P., additional, Gonzalez Vilchez, F., additional, Gonzalez Fernandez, C., additional, Zurbano Goni, F., additional, Cifrian Martinez, J., additional, Mons Lera, R., additional, Ruano Calvo, J., additional, Martin Duran, R., additional, Vazquez De Prada Tiffe, J., additional, Pietrzak, R., additional, Werner, B., additional, Voillot, D., additional, Huttin, O., additional, Zinzius, P., additional, Schwartz, J., additional, Sellal, J., additional, Lemoine, S., additional, Christophe, C., additional, Popovic, B., additional, Juilliere, Y., additional, Selton-Suty, C., additional, Ishii, K., additional, Furukawa, A., additional, Nagai, T., additional, Kataoka, K., additional, Seino, Y., additional, Shimada, K., additional, Yoshikawa, J., additional, Tekkesin, A., additional, Yildirimturk, O., additional, Tayyareci, Y., additional, Yurdakul, S., additional, Aytekin, S., additional, Jaroch, J., additional, Loboz-Grudzien, K., additional, Bociaga, Z., additional, Kowalska, A., additional, Kruszynska, E., additional, Wilczynska, M., additional, Dudek, K., additional, Kakihara, R., additional, Naruse, C., additional, Hironaka, H., additional, Tsuzuku, T., additional, Cucchini, U., additional, Muraru, D., additional, Badano, L., additional, Solda', E., additional, Tuveri, M., additional, Al Nono, O., additional, Sarais, C., additional, Iliceto, S., additional, Santos, L., additional, Cortez-Dias, N., additional, Ribeiro, S., additional, Goncalves, S., additional, Jorge, C., additional, Carrilho-Ferreira, P., additional, Silva, D., additional, Silva-Marques, J., additional, Lopes, M., additional, Diogo, A., additional, Hristova, K., additional, Vassilev, D., additional, Pavlov, P., additional, Katova, T., additional, Simova, I., additional, Kostova, V., additional, Esposito, R., additional, Santoro, A., additional, Schiano Lomoriello, V., additional, Raia, R., additional, De Palma, D., additional, Dores, E., additional, De Simone, G., additional, Galderisi, M., additional, Zaborska, B., additional, Makowska, E., additional, Pilichowska, E., additional, Maciejewski, P., additional, Bednarz, B., additional, Wasek, W., additional, Stec, S., additional, Budaj, A., additional, Spinelli, L., additional, Morisco, C., additional, Assante Di Panzillo, E., additional, Crispo, S., additional, Di Marino, S., additional, Trimarco, B., additional, Farina, F., additional, Innelli, P., additional, Rapacciuolo, A., additional, Polgar, B., additional, Banyai, F., additional, Rokusz, L., additional, Tomcsanyi, I., additional, Vaszily, M., additional, Nieszner, E., additional, Borsanyi, T., additional, Kerecsen, G., additional, Preda, I., additional, Kiss, R. G., additional, Bull, S., additional, Suttie, J., additional, Augustine, D., additional, Francis, J., additional, Karamitsos, T., additional, Becher, H., additional, Prendergast, B., additional, Neubauer, S., additional, Myerson, S., additional, Lodge, F., additional, Broyd, C., additional, Milton, P., additional, Mikhail, G., additional, Mayet, J., additional, Davies, J., additional, Francis, D., additional, Clavel, M.-A., additional, Ennezat, P.-V., additional, Marechaux, S., additional, Dumesnil, J., additional, Bellouin, A., additional, Bergeron, S., additional, Meimoun, P., additional, Le Tourneau, T., additional, Pasquet, A., additional, Pibarot, P., additional, Herrmann, S., additional, Stoerk, S., additional, Niemann, M., additional, Hu, K., additional, Voelker, W., additional, Ertl, G., additional, Weidemann, F., additional, Aytekin, V., additional, Kogoj, P., additional, Ambrozic, J., additional, Bunc, M., additional, Di Salvo, G., additional, Rea, A., additional, Castaldi, B., additional, Gala, S., additional, D'aiello, A., additional, Mormile, A., additional, Pisacane, F., additional, Pacileo, G., additional, Russo, M., additional, Calabro, R., additional, Nguyen, L., additional, Ricksten, S.-E., additional, Jeppsson, A., additional, Schersten, H., additional, Boerlage-Van Dijk, K., additional, Yong, Z., additional, Bouma, B., additional, Koch, K., additional, Vis, M., additional, Piek, J., additional, Baan, J., additional, Scandura, S., additional, Ussia, G., additional, Caggegi, A., additional, Cammalleri, V., additional, Sarkar, K., additional, Mangiafico, S., additional, Chiaranda', M., additional, Imme', S., additional, Pistritto, A., additional, Tamburino, C., additional, Ring, L., additional, Nair, S., additional, Wells, F., additional, Shapiro, L., additional, Rusk, R., additional, Rana, B., additional, Madrid Marcano, G., additional, Solis Martin, J., additional, Gonzalez Mansilla, A., additional, Bravo, L., additional, Menarguez Palanca, C., additional, Munoz, P., additional, Bouza, E., additional, Yotti, R., additional, Bermejo Thomas, J., additional, Fernandez Aviles, F., additional, Tamayo, T., additional, Denes, M., additional, Balint, O., additional, Csepregi, A., additional, Csillik, A., additional, Erdei, T., additional, Temesvari, A., additional, Fernandez-Pastor, J., additional, Linde-Estrella, A., additional, Cabrera-Bueno, F., additional, Pena-Hernandez, J., additional, Barrera-Cordero, A., additional, Alzueta-Rodriguez, F., additional, De Teresa-Galvan, E., additional, Merlo, M., additional, Pinamonti, M., additional, Finocchiaro, G., additional, Pyxaras, S., additional, Barbati, G., additional, Buiatti, A., additional, Dilenarda, A., additional, Sinagra, G., additional, Kuperstein, R., additional, Freimark, D., additional, Hirsch, S., additional, Feinberg, M., additional, Arad, M., additional, Mitroi, C., additional, Garcia Lunar, I., additional, Monivas Palomero, V., additional, Mingo Santos, S., additional, Beltran Correas, P., additional, Gonzalez Lopez, E., additional, Garcia Pavia, P., additional, Gonzalez Mirelis, J., additional, Cavero Gibanel, M., additional, Alonso Pulpon, L., additional, Pinamonti, B., additional, Zaidi, A., additional, Ghani, S., additional, Sheikh, N., additional, Gati, S., additional, Howes, R., additional, Sharma, R., additional, Sharma, S., additional, Calcagnino, M., additional, O'mahony, C., additional, Coats, C., additional, Cardona, M., additional, Garcia, A., additional, Murphy, E., additional, Lachmann, R., additional, Mehta, A., additional, Hughes, D., additional, Elliott, P., additional, Di Bella, G., additional, Madaffari, A., additional, Donato, R., additional, Mazzeo, A., additional, Casale, M., additional, Zito, C., additional, Vita, G., additional, Carerj, S., additional, Marek, D., additional, Indrakova, J., additional, Rusinakova, Z., additional, Skala, T., additional, Kocianova, E., additional, Taborsky, M., additional, Musca, F., additional, De Chiara, B., additional, Belli, O., additional, Cataldo, S., additional, Brunati, C., additional, Colussi, G., additional, Quattrocchi, G., additional, Santambrogio, G., additional, Spano, F., additional, Moreo, A., additional, Rustad, L., additional, Nytroen, K., additional, Gullestad, L., additional, Amundsen, B., additional, Aakhus, S., additional, Maroz-Vadalazhskaya, N., additional, Shumavetc, V., additional, Kurganovich, S., additional, Seljun, Y., additional, Ostrovskiy, A., additional, Ostrovskiy, Y., additional, Segers, P., additional, Orda, A., additional, Karolko, B., additional, Driessen, M. M. P., additional, Eising, J. B., additional, Uiterwaal, C., additional, Van Der Ent, C. K., additional, Meijboom, F. J., additional, Shang, Q., additional, Tam, L., additional, Sun, J., additional, Sanderson, J., additional, Zhang, Q., additional, Li, E., additional, Yu, C., additional, Arroyo Ucar, E., additional, De La Rosa Hernandez, A., additional, Hernandez Garcia, C., additional, Jorge Perez, P., additional, Lacalzada Almeida, J., additional, Jimenez Rivera, J., additional, Duque Garcia, A., additional, Barragan Acea, A., additional, Laynez Cerdena, I., additional, Kaldararova, M., additional, Simkova, I., additional, Pacak, J., additional, Tittel, P., additional, Masura, J., additional, Tadic, M., additional, Ivanovic, B., additional, Zlatanovic, M., additional, Damjanov, N., additional, Maggiolini, S., additional, Gentile, G., additional, Bozzano, A., additional, Suraci, S., additional, Meles, E., additional, Carbone, C., additional, Tempesta, A., additional, Malafronte, C., additional, Piatti, L., additional, Achilli, F., additional, Luijendijk, P., additional, Stevens, A., additional, De Bruin-Bon, H., additional, Vriend, J., additional, Van Den Brink, R., additional, Vliegen, H., additional, Mulder, B., additional, Chow, V., additional, Ng, A., additional, Chung, T., additional, Kritharides, L., additional, Iancu, M., additional, Serban, M., additional, Craciunescu, I., additional, Hodo, A., additional, Ghiorghiu, I., additional, Popescu, B., additional, Ginghina, C., additional, Styczynski, G., additional, Szmigielski, C. A., additional, Kaczynska, A., additional, Leszczynski, J., additional, Rosinski, G., additional, Kuch-Wocial, A., additional, Slavich, M., additional, Ancona, M., additional, Fisicaro, A., additional, Oppizzi, M., additional, Marone, E., additional, Bertoglio, L., additional, Melissano, G., additional, Margonato, A., additional, Chiesa, R., additional, Agricola, E., additional, Mohammed, M., additional, Cusma-Piccione, M., additional, Piluso, S., additional, Arcidiaco, S., additional, Nava, R., additional, Giuffre, R., additional, Ciraci, L., additional, Ferro, M., additional, Uusitalo, V., additional, Luotolahti, M., additional, Pietila, M., additional, Wendelin-Saarenhovi, M., additional, Hartiala, J., additional, Saraste, M., additional, Knuuti, J., additional, Saraste, A., additional, Kochanowski, J., additional, Scislo, P., additional, Piatkowski, R., additional, Grabowski, M., additional, Marchel, M., additional, Roik, M., additional, Kosior, D., additional, Opolski, G., additional, Bartko, P. E., additional, Graf, S., additional, Khorsand, A., additional, Rosenhek, R., additional, Burwash, I., additional, Beanlands, R., additional, Baumgartner, H., additional, Mundigler, G., additional, Kudrnova, S., additional, Apor, A., additional, Huttl, H., additional, Mori, F., additional, Santoro, G., additional, Oddo, A., additional, Rosso, G., additional, Meucci, F., additional, Pieri, F., additional, Squillantini, G., additional, Gensini, G., additional, Postula, M., additional, Park, D.-G., additional, Hong, J.-Y., additional, Kim, S.-E., additional, Lee, J.-H., additional, Han, K.-R., additional, Oh, D.-J., additional, Dal Bianco, L., additional, Beraldo, M., additional, Peluso, D., additional, Al Mamary, A., additional, Aggeli, C., additional, Felekos, I., additional, Poulidakis, E., additional, Pietri, P., additional, Roussakis, G., additional, Siasos, G., additional, Stefanadis, C., additional, Hoshiba, H., additional, Miyasaka, C., additional, Sato, H., additional, Yamanaka, A., additional, Lilli, A., additional, Baratto, M., additional, Magnacca, M., additional, Comella, A., additional, Poddighe, R., additional, Talini, E., additional, Canale, M., additional, Chioccioli, M., additional, Del Meglio, J., additional, Casolo, G., additional, Kuznetsov, V. A., additional, Melnikov, N. N., additional, Krinochkin, D. V., additional, Calin, A., additional, Enache, R., additional, Beladan, C., additional, Rosca, M., additional, Lupascu, L., additional, Purcarea, F., additional, Calin, C., additional, Gurzun, M., additional, Dulgheru, R., additional, Ciobanu, A., additional, Magda, S., additional, Mihaila, S., additional, Rimbas, R., additional, Margulescu, A., additional, Cinteza, M., additional, Vinereanu, D., additional, Sumin, A. N., additional, Arhipov, O., additional, Yoon, J., additional, Moon, J., additional, Rim, S., additional, Nyktari, E., additional, Patrianakos, A., additional, Solidakis, G., additional, Psathakis, E., additional, Parthenakis, F., additional, Vardas, P., additional, Kordybach, M., additional, Kowalski, M., additional, Kowalik, E., additional, Hoffman, P., additional, Nagy, K. V., additional, Kutyifa, V., additional, Edes, E., additional, Merkely, B., additional, Gerlach, A., additional, Rost, C., additional, Schmid, M., additional, Rost, M., additional, Flachskampf, F., additional, Daniel, W., additional, Breithardt, O., additional, Altekin, E., additional, Karakas, S., additional, Yanikoglu, A., additional, Er, A., additional, Baktir, A., additional, Demir, I., additional, Deger, N., additional, Klitsie, L., additional, Hazekamp, M., additional, Roest, A., additional, Van Der Hulst, A., additional, Gesink- Van Der Veer, B., additional, Kuipers, I., additional, Blom, N., additional, Ten Harkel, A., additional, Farsalinos, K., additional, Tsiapras, D., additional, Kyrzopoulos, S., additional, Avramidou, E., additional, Vasilopoulou, D., additional, Voudris, V., additional, Florianczyk, T., additional, Kalinowski, M., additional, Szulik, M., additional, Streb, W., additional, Rybus-Kalinowska, B., additional, Sliwinska, A., additional, Stabryla, J., additional, Kukla, M., additional, Nowak, J., additional, Kalarus, Z., additional, Florescu, M., additional, Mihalcea, D., additional, Magda, L., additional, Suran, B., additional, Enescu, O., additional, Mincu, R., additional, Salerno, G., additional, Scognamiglio, G., additional, D'andrea, A., additional, Dinardo, G., additional, Gravino, R., additional, Sarubbi, B., additional, Disalvo, G., additional, Liao, J.-N., additional, Sung, S., additional, Chen, C., additional, Park, S., additional, Shin, S., additional, Kim, M., additional, Shim, S., additional, Helvacioglu, F., additional, Ulusoy, O., additional, Duran, C., additional, Kirschner, R., additional, Simor, T., additional, Ambrosio, G., additional, Tran, T., additional, Raman, S., additional, Vidal Perez, R. C., additional, Carreras, F., additional, Leta, R., additional, Pujadas, S., additional, Barros, A., additional, Hidalgo, A., additional, Alomar, X., additional, Pons-Llado, G., additional, Olofsson, M., additional, Boman, K., additional, Ledakowicz-Polak, A., additional, Polak, L., additional, Zielinska, M., additional, Fontana, A., additional, Schirone, V., additional, Mauro, A., additional, Zambon, A., additional, Giannattasio, C., additional, Trocino, G., additional, Dekleva, M., additional, Dungen, H., additional, Inkrot, S., additional, Gelbrich, G., additional, Suzic Lazic, J., additional, Kleut, M., additional, Markovic Nikolic, N., additional, Waagstein, F., additional, Khoor, S., additional, Balogh, N., additional, Simon, I., additional, Fugedi, K., additional, Kovacs, I., additional, Khoor, M., additional, Florian, G., additional, Kocsis, A., additional, Szuszai, T., additional, O'driscoll, J., additional, Saha, A., additional, Smith, R., additional, Gupta, S., additional, Lenkey, Z., additional, Gaszner, B., additional, Illyes, M., additional, Sarszegi, Z., additional, Horvath, I. G., additional, Magyari, B., additional, Molnar, F., additional, Cziraki, A., additional, Elnoamany, M. F., additional, Badran, H., additional, Ebraheem, H., additional, Reda, A., additional, and Elsheekh, N., additional

Published
2011
Full Text
View/download PDF

10. Learning Curve for Starting a Successful Single-Centre TAVR Programme with Multiple Devices: Early and Mid-Term Follow-Up.

Author

Magyari B, Kittka B, Goják I, Schönfeld K, Szapáry LB, Simon M, Kiss R, Bertalan A, Várady E, Gyimesi A, Szokodi I, and Horváth IG

Abstract

Aims: We report 30-day, 1-year, and 3-year outcomes for a new TAVR programme that used five different transcatheter heart valve (THV) systems. Methods: From 2014 to 2020, 122 consecutive patients with severe aortic stenosis (AS) received TAVR based on the Heart Team decision. Outcomes were analysed for the whole study population and in addition the first 63 patients (Cohort A, 2014 to 2019) were compared to the last 59 patients (Cohort B, 2019 to 2020). Outcomes included VARC-2 definitions and device performance assessed via transthoracic echocardiography by independent high-volume investigators. Results: The mean patient age was 77.9 ± 6.1 years old, and 48 (39.3%) were male. The mean logistic Euroscore II was 4.2 ± 4.5, and the mean STS score was 6.9 ± 4.68. The systems used were as follows: Medtronic Corevalve Evolute R/PRO (82 patients-67.2%); Abbott Portico (13-10.6%); Boston Scientific Lotus (10-8.2%); Meril Myval (11-9%); and Boston Scientific Neo Accurate (6-5%). Access was transfemoral (95.9% of patients); surgical cut down (18% vs. percutaneous 77.8%); subclavian ( n = 2); trans-axillary ( n = 2); and direct aorta ( n = 1). VARC-2 outcomes were as follows: device success rate 97.5%; stroke rate 1.6%; major vascular complication 3.3%; permanent pacemaker implantation 12.4%. At discharge, the incidences of grade I and II aortic regurgitation were 39.95 and 55.5%, respectively. At one year, all-cause mortality was 7.4% without admissions for valve-related dysfunction. The 3-year all-cause mortality and all-stroke rates were 22.9% and 4.1%, respectively. Between the 1-year and 3-year follow-ups, valve-related dysfunction was detected in three patients; one had THV system endocarditis that led to death. There was a remarkable but statistically non-significant decrease in mortality from Cohort A to Cohort B [four (6.3%) vs. one patient (1.7%), p = 0.195] and major vascular complications occurred at a significantly higher rate in the Cohort B [zero (0%) vs. four (6.8% patient, p = 0.036)]. Overall, we found that using multiple devices was safe and allowed for a learning team to achieve a high device success rate from the beginning (97.5%). Conclusions: TAVR with different THV systems showed acceptable early and mid-term outcomes for survival, technical success, and valve-related adverse events in high-risk patients with significant AS, even in the learning curve phase.

Published
2024
Full Text
View/download PDF

11. Single-Center Experience with the Balloon-Expandable Myval Transcatheter Aortic Valve System in Patients with Bicuspid Anatomy: Procedural and 30-Day Follow-Up.

Author

Magyari B, Kittka B, Goják I, Schönfeld K, Szapáry LB, Simon M, Kiss R, Bertalan A, Várady E, Gyimesi A, Szokodi I, and Horváth IG

Abstract

Aims: To report our single-center data regarding the initial 52 consecutive patients with a bicuspid aortic valve who underwent a Transcatheter Aortic Valve Implantation (TAVI) procedure using the new balloon-expandable MYVAL system. The focus is on reporting procedural details and outcomes over the 30-day postoperative period. Methods: From December 2019 to July 2023, 52 consecutive patients underwent a TAVI procedure with bicuspid anatomy. All patients had moderate to-high surgical risk or were unsuitable for surgical aortic valve replacement based on the Heart Team's decision. Outcomes were analyzed according to the VARC-2 criteria. The results of bicuspid patients were compared to patients with tricuspid anatomy in the overall study group, and further analysis involved a comparison between 52 pairs after propensity score matching. The device performance was evaluated using transthoracic echocardiography. Data collection was allowed by the Local Ethical Committee. Results: The mean age was 71 ± 7.1 years, and 65.4% were male. The mean Euroscore II and STS score were 3.3 ± 3.2 and 5.2 ± 3.3, respectively. Baseline characteristics and echocardiographic parameters were well balanced even in the unmatched comparison. Procedures were significantly longer in the bicuspid group and resulted in a significantly higher ARI index. All relevant anatomic dimensions based on the CT scans were significantly higher in bicuspid anatomy, including a higher implantation angulation, a higher rate of horizontal aorta and a higher proportion of patients with aortopathy. In the unmatched bicuspid vs. tricuspid comparison, postprocedural outcomes were as follows: in-hospital mortality 0% vs. 1.4% ( p = 0.394), device success 100% vs. 99.1% ( p = 0.487), TIA 1.9% vs. 0% ( p = 0.041), stroke 1.9% vs. 0.9% ( p = 0.537), major vascular complication 3.8% vs. 2.3% ( p = 0.530), permanent pacemaker implantation 34% vs. 30.4% ( p = 0.429), and cardiac tamponade 0% vs. 0.5% ( p = 0.624). In the propensity-matched bicuspid vs. tricuspid comparison, postprocedural outcomes were as follows: in-hospital mortality 0% vs. 0%, device success 100% vs. 100%, TIA 1.9% vs. 0% ( p = 0.315), stroke 1.9% vs. 0.9% ( p = 0.315), major vascular complication 3.8% vs. 0% ( p = 0.475), permanent pacemaker implantation 34% vs. 24% ( p = 0.274), and cardiac tamponade 0% vs. 0%. There was no annular rupture nor need for second valve or severe aortic regurgitation in both the unmatched and matched comparison. The peak and mean aortic gradients did not differ at discharge and at 30-day follow-up between the two groups regardless of whether the comparison was unmatched or matched. There were no paravalvular leakages (moderate or above) in the bicuspid patients. Intermediate and extra sizes of the Myval THV system used a significantly higher proportion in bicuspid anatomy with a significantly higher oversize percentage in tricuspid anatomy. Conclusions: The TAVI procedure using the Myval THV system in patients with significant aortic stenosis and bicuspid aortic valve anatomy is safe and effective. Hemodynamic parameters do not differ between tricuspid and bicuspid patients. However, the permanent pacemaker implantation rate is higher than expected; its relevance on long-term survival is controversial.

Published
2024
Full Text
View/download PDF

12. Single center experience with the balloon-expandable Myval transcatheter aortic valve system with the first 100 patients: 30-day and 1-year follow-up.

Author

Magyari B, Kittka B, Goják I, Kasza G, Schönfeld K, Szapáry LB, Simon M, Kiss R, Bertalan A, Várady E, Gyimesi A, Szokodi I, and Horváth I

Subjects
Humans, Male, Aged, Female, Aortic Valve diagnostic imaging, Aortic Valve surgery, Follow-Up Studies, Retrospective Studies, Treatment Outcome, Prosthesis Design, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis
Abstract

Aims: To report our single-center data, regarding the first 100 patients who underwent TAVR procedure with the new balloon-expandable MYVAL system. We report 30-day and 1-year outcomes in low to high-risk TAVR patient population., Methods: From November 2019 to July 2021, 100 consecutive patients underwent TAVR procedure. Patient outcome was classified according to the VARC-2 definitions. The device performance was assessed using transthoracic echocardiography. Data collection was allowed by the Local Ethical Committee., Results: The mean age was 74.7 years, 63 (63%) were male. The mean Euroscore II and STS score were 4.8 ± 4.9 and 5.6 ± 3.9, respectively. Transfemoral access was the most frequent (surgical vs. percutaneous 2% vs. 97%) and in one patient surgical subclavian access was used. VARC-2 outcomes were as follows: device success 99%, STROKE 1%, major and minor vascular complication was 1% and 11%, respectively, the rate of new permanent pacemaker implantation was 30.7%. At discharge, the incidence of grade I, grade II aortic regurgitation was 39% and 1%, respectively, without relevant PVL. In-hospital mortality was only 1%. These results included a high proportion (17%) of patients with bicuspid aortic valves. At 1 year, the all-cause mortality rate was 7% (only two due to cardiac event) and only a single patient had valve-related dysfunction requiring surgical aortic replacement., Conclusions: TAVR procedure with MYVAL transcatheter heart valve system shows excellent 30-day and 1-year outcomes regarding patient survival, technical success, and valve-related adverse events. The limitations of our study comprise a single-center study with retrospective data collection., (© 2023 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

13. The Effect of Magnesium on Reperfusion Arrhythmias in STEMI Patients, Treated With PPCI. A Systematic Review With a Meta-Analysis and Trial Sequential Analysis.

Author

Szapary LB, Szakacs Z, Farkas N, Schonfeld K, Babocsay D, Gajer M, Kittka B, Magyari B, Hegyi P, Szokodi I, and Horvath IG

Abstract

Aims: The restoration of coronary circulation plays a crucial role in treating ST-segment elevation myocardial infarction (STEMI), however successful reperfusion with primary percutaneous coronary intervention (PPCI) may induce life-threatening arrhythmias. The relation between myocardial electrical instability, as a background factor in reperfusion arrhythmia, and magnesium administered periprocedurally is still questionable. Several randomized clinical trials have been conducted predominantly in the thrombolysis era. Due to the contradictory results of these studies, there is little evidence of the potential preventive effect of magnesium on reperfusion arrhythmias. The aim of our study is to review and meta-analytically analyze data from all studies published so far in the PPCI era, comparing STEMI patients who have undergone primary PCI and received either magnesium or a placebo before the reperfusion procedure. Methods and Results: Our meta-analysis follows the points in the PRISMA protocol and, meets all of their criteria. We conducted a search in five scientific databases using the following keyword combination: (myocardial infarction OR myocardial injury OR acute coronary syndrome OR acs OR stemi) AND magnesium. The 7,295 collected publications were filtered with the Endnote program by title, abstract and full-text based on predefined criteria. A statistical analysis was performed on three randomized-controlled trials using three common parameters, involving 336 patients Trial sequential analysis (TSA) was applied to assess the risk of random error associated with sparse data and multiple testing which can affect cumulative meta-analysis. The incidence of ventricular tachycardias (VTs) was not significantly increased in the non-magnesium control group. (OR: 1.36; CI: 0.619; -2.986, P = 0.263). For the ejection fraction (EF), a non-significant decrease was observed in the magnesium group by weighted mean difference calculation. (WMD: 7.262, 95% CI: -0.238; 0.053; P = 0.057). There was significant decrease in the infarct zone wall motion index (IZWMSI) in the magnesium treatment group. (WMD: 0.384, 95% CI: -0.042; 0.811, P = 0.015). Based on the TSA assessments, the results of all parameters are not significant, objectively demonstrating the lack of reasonable data pertaining to our question. Conclusions: The preventive effect of magnesium on reperfusion arrhythmia associated with primary PCI can still be considered contradictory based on previous studies. In our study, we found, that magnesium is ineffective with a very weak evidence, due to the small number of patients and the biases of the included studies, and a well-designed clinical trial is needed in this area, based on the TSA., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Szapary, Szakacs, Farkas, Schonfeld, Babocsay, Gajer, Kittka, Magyari, Hegyi, Szokodi and Horvath.)

Published
2021
Full Text
View/download PDF

14. Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity.

Author

Tornyos A, Aradi D, Horváth IG, Kónyi A, Magyari B, Pintér T, Vorobcsuk A, Tornyos D, and Komócsi A

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Treatment Outcome, Blood Platelets immunology, Coronary Restenosis therapy, Drug-Eluting Stents adverse effects
Abstract

Background: The impact of high platelet reactivity (HPR) on clinical outcomes after elective percutaneous coronary interventions (PCI) with drug-eluting balloons (DEB) due to in-stent restenosis (ISR) is unknown., Objective: We sought to evaluate the prognostic importance of HPR together with conventional risk factors in patients treated with DEB., Methods: Patients treated with DEB due to ISR were enrolled in a single-centre, prospective registry between October 2009 and March 2015. Only patients with recent myocardial infarction (MI) received prasugrel, others were treated with clopidogrel. HPR was defined as an ADP-test >46U with the Multiplate assay and no adjustments were done based on results. The primary endpoint of the study was a composite of cardiovascular mortality, MI, any revascularization or stroke during one-year follow-up., Results: 194 stable angina patients were recruited of whom 90% were treated with clopidogrel. Clinical characteristics and procedural data were available for all patients; while platelet function testing was performed in 152 subjects of whom 32 (21%) had HPR. Patients with HPR had a higher risk for the primary endpoint (HR: 2.45; CI: 1.01-5.92; p = 0.03). The difference was primarily driven by a higher risk for revascularization and MI. According to the multivariate analysis, HPR remained a significant, independent predictor of the primary endpoint (HR: 2.88; CI: 1.02-8.14; p = 0.04), while total DEB length and statin treatment were other independent correlates of the primary outcome., Conclusion: HPR was found to be an independent predictor of repeat revascularization and MI among elective patients with ISR undergoing PCI with DEB.

Published
2017
Full Text
View/download PDF

15. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.

Author

Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, and Komócsi A

Subjects
Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome therapy, Aged, Angioplasty, Balloon, Coronary methods, Clopidogrel, Combined Modality Therapy, Confidence Intervals, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage prevention & control, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction prevention & control, Piperazines adverse effects, Platelet Function Tests, Prasugrel Hydrochloride, Predictive Value of Tests, Proportional Hazards Models, Prospective Studies, Registries, Risk Assessment, Severity of Illness Index, Stroke prevention & control, Survival Rate, Thiophenes adverse effects, Thrombosis prevention & control, Ticlopidine administration & dosage, Ticlopidine adverse effects, Treatment Outcome, Acute Coronary Syndrome drug therapy, Acute Coronary Syndrome mortality, Cause of Death, Piperazines administration & dosage, Purinergic P2Y Receptor Antagonists administration & dosage, Stents, Thiophenes administration & dosage, Ticlopidine analogs & derivatives
Abstract

Objectives: This study sought to evaluate the impact of treatment with prasugrel and high-dose clopidogrel on the basis of platelet function testing in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI)., Background: The clinical impact of treatment with prasugrel in patients with ACS who have high platelet reactivity (HPR) is unknown., Methods: Patients with ACS who were pre-treated with clopidogrel and undergoing successful PCI were enrolled in a single-center, prospective registry. Platelet function was measured 12 to 36 h after PCI with the Multiplate device (Roche Diagnostics GmbH, Mannheim, Germany). Patients with HPR (>46 U) were switched to prasugrel or treated with high-dose clopidogrel, and those without HPR continued treatment with 75 mg of clopidogrel., Results: A total of 741 consecutive patients were enrolled in the study between September 2011 and August 2012, and 219 of these patients (29.5%) had HPR. Although platelet reactivity decreased after treatment adjustments in those with HPR, prasugrel provided significantly more potent platelet inhibition compared with high-dose clopidogrel (p < 0.0001). Compared with patients without HPR, the risk of all-cause death, myocardial infarction, stent thrombosis, or stroke at 1 year was significantly higher in the high-dose clopidogrel group (hazard ratio [HR]: 2.27; 95% confidence interval [CI]: 1.45 to 3.55; p < 0.0001), and patients who were switched to prasugrel had similar outcomes (HR: 0.90; 95% CI: 0.44 to 1.81; p = 0.76). Bleeding Academic Research Consortium (BARC) type 3/5 bleeding was also more frequent in patients treated with high-dose clopidogrel (HR: 2.09; 95% CI: 1.05 to 4.17; p = 0.04) than in patients switched to prasugrel (HR: 0.45; 95% CI: 0.11 to 1.91; p = 0.28). In a multivariate model, HPR with high-dose clopidogrel, but not with prasugrel, was an independent predictor of the composite ischemic endpoint (HR: 1.90; 95% CI: 1.17 to 3.08; p = 0.01)., Conclusions: Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel., (Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2014
Full Text
View/download PDF

16. Evaluation of experimental myocardial infarction models via electromechanical mapping and magnetic resonance imaging.

Author

Lukács E, Magyari B, Tóth L, Petneházy Ö, Petrási Z, Simor T, Gyöngyösi M, Repa I, Koller Á, Rőth E, and Horváth IG

Subjects
Animals, Coronary Angiography, Myocardial Infarction etiology, Myocardial Infarction pathology, Myocardial Infarction physiopathology, ROC Curve, Sensitivity and Specificity, Sus scrofa, Body Surface Potential Mapping methods, Disease Models, Animal, Magnetic Resonance Imaging methods, Myocardial Infarction diagnosis
Abstract

The diagnostic characteristics of electromechanical mapping (EMM) were evaluated in porcine myocardial infarction (MI) models with the parallel application of cardiac magnetic resonance imaging (cMRI) from the aspect of different pathophysiology and localization. Balloon occlusion in the left anterior descending coronary artery (LAD balloon group) or coil deployment in the LAD (LAD coil group) or circumflex artery (Cx coil group) was applied percutaneously in 16 domestic pigs. Regional left ventricular viability data were captured via cMRI and EMM. The unipolar voltage (UV) value was significantly decreased in segments containing transmural and subendocardial late enhancement compared with viable segments in the LAD balloon, LAD coil, and Cx coil groups. Receiver operating characteristic analysis revealed area under the curve values of 0.809 and 0.691 in the LAD infarct territory, and 0.864 and 0.855 in the Cx infarct territory for the UV compared with cMRI viability results as transmural late enhancement or viable tissue and subendocardial late enhancement or viable tissue, respectively. In conclusion, the UV value detected the presence of scar tissue with differential transmural extent and which represented proper diagnostic features both in the reperfused and nonreperfused models. This data could provide additional benefit in the clinical use of EMM for diagnostic purposes.

Published
2013
Full Text
View/download PDF

17. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.

Author

Aradi D, Rideg O, Vorobcsuk A, Magyarlaki T, Magyari B, Kónyi A, Pintér T, Horváth IG, and Komócsi A

Subjects
Aged, Clopidogrel, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Platelet Function Tests, Stroke prevention & control, Thrombosis prevention & control, Ticlopidine administration & dosage, Time Factors, Angina, Stable drug therapy, Blood Platelets drug effects, Cell Adhesion Molecules drug effects, Microfilament Proteins drug effects, Phosphoproteins drug effects, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors administration & dosage, Ticlopidine analogs & derivatives
Abstract

Background: The GRAVITAS trial showed that 150 mg clopidogrel did not improve outcome in patients with high on-clopidogrel platelet reactivity (HPR) screened by the VerifyNow assay. We aimed to determine the impact of 150 mg clopidogrel in stable angina patients with HPR identified with conventional aggregometry (LTA)., Materials and Methods: Clopidogrel-naive stable angina patients before ad hoc percutaneous coronary intervention were recruited into a randomized, double-blind, placebo-controlled trial (NCT00638326). Twelve to 24 h after the 600-mg loading dose of clopidogrel, ADP(5μM)-stimulated maximal (AGGmax), late platelet aggregation (AGGlate) and vasodilator-stimulated phosphoprotein phosphorylation (VASP-PRI) were evaluated. Patients with HPR (AGGmax ≥ 34%) were randomly allocated to 75 or 150 mg clopidogrel after 4 weeks. After control platelet function measurements at day 28, 75 mg clopidogrel was administered to all patients until 1 year., Results: The study was prematurely terminated at the stage of 200 enroled patients. Administration of 150 mg clopidogrel significantly reduced platelet aggregation (AGGmax: 45·0 ± 6·8 vs. 33·8 ± 15·1, P < 0·01; AGGlate: 27·1 ± 14·7 vs. 13·8 ± 18·0, P < 0·01) and VASP-PRI (57·5 ± 15·2 vs. 37·2 ± 17·1; P < 0·01), while platelet reactivity remained unchanged in patients with HPR receiving 75 mg clopidogrel. The higher maintenance dose of clopidogrel was associated with a significant reduction in cardiovascular (CV) death and myocardial infarction (MI) (0% vs. 11·4%, P = 0·04) and in CV death, MI or target vessel revascularization (24·6% vs. 3·1%; P = 0·01) during 1 year., Conclusions: One-month administration of 150 mg maintenance dose of clopidogrel reduces platelet reactivity and might decrease the risk of thrombo-ischaemic complications in stable angina patients with HPR identified by LTA., (© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.)

Published
2012
Full Text
View/download PDF

18. Comparison of aortic and carotid arterial stiffness parameters in patients with verified coronary artery disease.

Author

Gaszner B, Lenkey Z, Illyés M, Sárszegi Z, Horváth IG, Magyari B, Molnár F, Kónyi A, and Cziráki A

Subjects
Adult, Aged, Aged, 80 and over, Blood Flow Velocity, Coronary Angiography, Echocardiography, Doppler, Female, Humans, Male, Middle Aged, Oscillometry, Predictive Value of Tests, Pulsatile Flow, Aorta physiopathology, Carotid Arteries physiopathology, Coronary Artery Disease physiopathology, Vascular Stiffness physiology
Abstract

Background: Arterial stiffness parameters are commonly used to determine the development of atherosclerotic disease. The independent predictive value of aortic stiffness has been demonstrated for coronary events., Hypothesis: The aim of our study was to compare regional and local arterial functional parameters measured by 2 different noninvasive methods in patients with verified coronary artery disease (CAD). We also compared and contrasted these stiffness parameters to the coronary SYNTAX score in patients who had undergone coronary angiography., Methods: In this study, 125 CAD patients were involved, and similar noninvasive measurements were performed on 125 healthy subjects. The regional velocity of the aortic pulse wave (PWVao) was measured by a novel oscillometric device, and the common carotid artery was studied by a Doppler echo-tracking system to determine the local carotid pulse wave velocity (PWVcar). The augmentation index (AIx), which varies proportionately with the resistance of the small arteries, was recorded simultaneously., Results: In the CAD group, the PWVao and aortic augmentation index (Alxao) values increased significantly (10.1 ± 2.3 m/sec and 34.2% ± 14.6%) compared to the control group (9.6 ± 1.5 m/sec and 30.9% ± 12%; P < 0.05). We observed similar significant increases in the local stiffness parameters (PWVcar and carotid augmentation index [Alxcar]) in patients with verified CAD. Further, we found a strong correlation for PWV and AIx values that were measured with the Arteriograph and those obtained using the echo-tracking method (r = 0.57, P < 0.001 for PWV; and r = 0.65, P < 0.001 for AIx values)., Conclusions: Our results indicate that local and regional arterial stiffness parameters provide similar information on impaired arterial stiffening in patients with verified CAD., (© 2011 Wiley Periodicals, Inc.)

Published
2012
Full Text
View/download PDF

19. Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies.

Author

Pintér T, Faludi R, Magyari B, Vorobcsuk A, Kumánovics G, Minier T, Czirják L, and Komócsi A

Subjects
Adaptation, Physiological physiology, Aged, Case-Control Studies, Coronary Angiography, Echocardiography, Endovascular Procedures instrumentation, Female, Heart physiopathology, Humans, Male, Middle Aged, Vasodilation physiology, Blood Pressure physiology, Coronary Vessels physiopathology, Endovascular Procedures methods, Regional Blood Flow physiology, Scleroderma, Systemic physiopathology
Abstract

Objective: Functional impairment of coronary microcirculation is thought to be a major pathway in the development of primary cardiac involvement in SSc; however, the underlying mechanism is not fully understood. We aimed to investigate the mechanisms of coronary flow reserve (CFR) reduction in patients with SSc., Methods: Seventeen SSc patients and 17 gender- and age-matched controls were enrolled. Coronary angiography and determination of coronary flow parameters including index of myocardial resistance (IMR) using intracoronary pressure wire at basal conditions and during vasodilator-induced maximal hyperaemia were performed. Transit times of repeated intracoronary saline injection were measured to evaluate the role of cold exposure., Results: SSc patients with decreased CFR had accelerated basal coronary flow velocity (P < 0.05), and their IMR in hyperaemia (IMR(hyp)) did not differ from either SSc patients with normal CFR or from the controls (P = 0.292 and P =  0.308). The coronary flow velocity of SSc patients correlated with the IMR at baseline (IMR(bas)) (r  = 0.56, P  = 0.019). Injection of room temperature saline did not provoke changes in coronary transit times., Conclusions: The lack of decrease in the maximal vasodilatation response indicates that there is no irreversible functional damage at the level of the coronary arterioles. In patients with reduced CFR, the decreased basal IMR and higher velocity reflect compensatory vasodilatory mechanisms probably triggered by ischaemic signals deriving from abnormal myocardial microcirculation.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results